Abstracts tagged "SLE"

Abstract Number: 1604 • 2014 ACR/ARHP Annual Meeting
IFN-γ (Th₁), IL4 (Th₂), and IL5 (Th₂) Are Elevated in Pre-Clinical SLE and Predict Transition to Classified Disease Prior to Appearance of Autoantibodies or Clinical Criteria
Rufei Lu^1,2, Melissa E. Munroe³, Joel M. Guthridge², Krista M. Bean², Dustin Fife², John B. Harley⁴, Judith A. James⁵ and Michael P. Keith⁶, ¹Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose Systemic Lupus Erythematosus (SLE) is a clinically diverse autoimmune disease that often begins with a pre-disease period of autoantibody production and symptom accrual.…
Abstract Number: 688 • 2014 ACR/ARHP Annual Meeting
Corticosteroids in Early Treatment Pathways in SLE
John G. Hanly¹, Amyn Sayani², Steve Doucette³, Sandra Iczkovitz² and Jorge Alfonso Ross², ¹Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ²Medical Affairs, GlaxoSmithKline, Mississauga, ON, Canada, ³Dalhousie University and Capital Health, Halifax, NS, Canada
Background/Purpose: The treatment algorithm for patients with new onset systemic lupus erythematosus (SLE) is more variable than that for other rheumatic diseases (e.g. rheumatoid arthritis).…
Abstract Number: 2955 • 2014 ACR/ARHP Annual Meeting
The Impact of Northern European Ancestry and Susceptibility Loci on the Risk of Lupus Nephritis
Sarah French¹, Kimberly E. Taylor², Sharon A. Chung¹, Joanne Nitiham³, Michelle Petri⁴, Peter K. Gregersen⁵, Ward Ortmann⁶, Annette T. Lee⁷, Timothy W. Behrens⁶, Susan Manzi⁸, F. Yesim Demirci⁹, M. Ilyas Kamboh¹⁰, Robert R. Graham⁶, Michael F. Seldin¹¹ and Lindsey A. Criswell³, ¹School of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁶ITGR Human Genetics, Genentech, Inc., South San Francisco, CA, ⁷Genomics & Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁸Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Human Genetics, University of Pittsburgh, Pittsburgh, PA, ¹¹Department of Biochemistry and Molecular Medicine, University of California, Davis, Davis, CA
Background/Purpose Lupus nephritis (LN) has a higher prevalence among African Americans, Hispanics, and Asians compared to Caucasians. Significant differences in SLE severity also exist within…
Abstract Number: 2652 • 2014 ACR/ARHP Annual Meeting
Headache in Patients with Systemic Lupus Erythematosus Is Associated with Reduced Cerebral Grey Matter Volume, but not with Measures of Glial Activation, Anti-NR2-, or Anti-P Antibodies
Anne B Tjensvoll¹, Maria B Lauvsnes², Shunsei Hirohata³, Jan T Kvaløy⁴, Mona K Beyer⁵, Erna Harboe⁶, Lasse G Gøransson⁶, Ole J Greve⁷ and Roald Omdal⁸, ¹Department of Neurology, Stavanger University Hospital, Stavanger, Norway, ²Department of Internal Medicine, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, ³Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ⁴Research Department, Stavanger University Hospital, Stavanger, Norway, ⁵Department of Radiology and Nuclear medicine, Oslo University Hospital, National Hospital, Oslo, Norway, ⁶Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁷Department of Radiology, Stavanger University Hospital, Stavanger, Norway, ⁸Department of Internal Medicin, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway
Background/Purpose: Headache, especially migraine, is frequent and one of the most common neuropsychiatric manifestations in systemic lupus erythematosus (SLE). A possible mechanism for this is…
Abstract Number: 1920 • 2014 ACR/ARHP Annual Meeting
Predicting SLE Disease Activity in the Next Year Based on Measures of Four Gene Transcripts and Two Proteins
Laurence S Magder¹, Eric Zollars², Jadwiga Bienkowska³, Chris Stebbins⁴, Carrie Wager⁵, Linda Burkly⁶, Nicolas Wisniacki⁷, Ann Ranger⁸ and Michelle Petri⁹, ¹Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Translational Medicine, Biogen Idec, Cambridge, MA, ⁵Biostatistics, Biogen Idec, Cambridge, MA, ⁶Biogen Idec, Cambridge, MA, ⁷Formerly with Biogen Idec, Cambridge, MA, ⁸14 Cambridge Center, Biogen Idec, Cambridge, MA, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose Multiple gene transcripts and proteins in blood or urine have been observed to correlate with disease activity in SLE. However some observed associations might…
Abstract Number: 1620 • 2014 ACR/ARHP Annual Meeting
Antibody to Malondialdehyde-Acetaldehyde Adducts (MAA) As a Potential Biomarker of Inflammation in Systemic Lupus Erythrematosus (SLE)
Andy Hollins¹, Michael Duryee², Michelene Hearth-Holmes³, Ted R. Mikuls¹, Zhixin Zhang⁴, Kaihong Su⁵ and Geoffrey M. Thiele⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine/Rheumatology Division, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁵Eppley Cancer Institute, University of Nebraska Medical Center, Omaha, NE, ⁶Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose Studies have shown that malondialdehyde-acetaldehyde (MAA) is formed as a result of lipid peroxidation of cellular membranes and is capable of binding or adducting…
Abstract Number: 686 • 2014 ACR/ARHP Annual Meeting
Clinicians Approaches to the Management of Background Therapy in SLE Patients in Clinical Remission: Results of an International Survey
Pintip Ngamjanyaporn^1,2, Ian Bruce³, Ben Parker⁴ and Jamie Sergeant¹, ¹Institute of Inflammation and Repair School of translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ²Internal Medicine, Mahidol University, Bangkok, Thailand, ³Kellgren Centre for Rheum, Arthritis Research UK Epidemiology Unit, Institution of Inflammation and Repair, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁴Institute of Inflammation and Repair School of Translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: At present there is no consensus on what constitutes a remission in SLE. In particular it is not clear how background therapy should be…
Abstract Number: 2837 • 2014 ACR/ARHP Annual Meeting
Induction of Clinical Remission By Low-Dose Interleukin-2 in Refractory SLE
Jens Y. Humrich¹, Caroline von Spee-Mayer¹, Elise Siegert¹, Angelika Rose¹, Tobias Alexander², Falk Hiepe¹, Andreas Radbruch³, Gerd Burmester⁴ and Gabriela Riemekasten¹, ¹Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ³German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, ⁴Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
Abstract Number: 2619 • 2014 ACR/ARHP Annual Meeting
Low Socioeconomic Status (SES) As Measured By Education Is (not) Associated with Worse Outcome in SLE: Data from the 1000 Canadian Faces of Lupus
Angela George¹, Christine Peschken², Earl Silverman³, Christian A. Pineau⁴, C Douglas Smith⁵, Hector Arbillaga⁶, Michel Zummer⁷, Ann Clarke⁸, Sasha Bernatsky⁹, Marie Hudson¹⁰, Carol A. Hitchon¹¹, Paul R. Fortin¹² and Janet E. Pope¹³, ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ³Pediatrics/Rheumatology, Toronto Hospital for Sick Children, U of Toronto, Toronto, ON, Canada, ⁴Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁵The Arthritis Centre, TOH Riverside Campus, Ottawa, ON, Canada, ⁶Medicine/Rheumatology, Lethbridge Rheumatology practice, Lethbridge, AB, Canada, ⁷Medicine/Rheumatology, U of Montreal, Montreal, QC, Canada, ⁸Medicine/Allergy, U of Calgary, Calgary, AB, Canada, ⁹Clinical Epidemiology, McGill UHC/RVH, Montreal, QC, Canada, ¹⁰Medicine/Rheumatology, McGill University, Montreal, QC, Canada, ¹¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹²Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada, ¹³St Joseph Health Care, London, ON, Canada
Background/Purpose: To determine whether socioeconomic status, as measured by education, impacts disease activity (measured by SLAM-2, SLEDAI-2K) or disease damage (measured by SLICC SDI) in…
Abstract Number: 1858 • 2014 ACR/ARHP Annual Meeting
Standardized Mortality Ratios for Cause-Specific Deaths in Lupus Patients Followed Prospectively at a Single Centre Lupus Clinic
Barry J. Sheane¹, Dominique Ibanez², Dafna D. Gladman³ and Murray B. Urowitz³, ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Despite the significant improvement in survival rates of patients with systemic lupus erythematosus (SLE) over the last four decades, mortality rates have remained at…
Abstract Number: 1310 • 2014 ACR/ARHP Annual Meeting
Predicting Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Patients at Diagnosis
Maya Gerstein¹, Roberto Ezequiel Borgia², Brian Feldman¹, Deborah M. Levy³, Sharon Sukhdeo⁴, Susanne M. Benseler⁵, Lawrence W.K. Ng¹, Mohamed Abdelhaleem⁶, Earl D. Silverman² and Linda T Hiraki⁷, ¹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, The Hospital For Sick Children, Toronto, ON, Canada, ⁵Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ⁶Department of Paediatric Laboratory Medicine, Division of Haematopathology, The Hospital for Sick Children, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose It can be difficult to differentiate macrophage activation syndrome (MAS) from active pediatric systemic lupus erythematosus (pSLE). However, this differentiation is in determining correct…
Abstract Number: 676 • 2014 ACR/ARHP Annual Meeting
Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Emily Sutton¹, Kath D. Watson², David A. Isenberg³, Anisur Rahman⁴, David Jayne⁵, Caroline Gordon⁶, Ben Parker⁷, David P. D'Cruz⁸, Munther A. Khamashta⁹, Pamela Lutalo¹⁰, Peter Lanyon¹¹, Benjamin Rhodes¹², Bridget Griffiths¹³, Edward M. Vital¹⁴, Chee-Seng Yee¹⁵, Christopher Edwards¹⁶, Mohammed Akil¹⁷, Nicola Erb¹⁸, Athiveer Prabu¹⁹, Asad A. Zoma²⁰, Neil McHugh²¹, Hazem Youssef²², Lee-Suan Teh²³, Michael W. Beresford²⁴ and Ian N. Bruce²⁵, ¹University of Manchester, Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ³Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research, University College London, London, United Kingdom, ⁵Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁶Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Institute of Inflammation and Repair School of Translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁸Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ⁹Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ¹⁰Peter Gorer Department of Immunobiology, King's College London School of Medicine, London, United Kingdom, ¹¹Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ¹²Rheumatology, Queen Elizabeth Hospital, Birmingham, United Kingdom, ¹³Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ¹⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., United Kingdom, Leeds, United Kingdom, ¹⁵Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, United Kingdom, ¹⁶Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹⁷Rheumatology Department, Sheffield South Yorkshire, United Kingdom, ¹⁸Rheumatology, Russells Hall Hospital, Dudley, United Kingdom, ¹⁹Department of Rheumatology, Worcester Acute Hospitals NHS Trust, Worcester, United Kingdom, ²⁰Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ²¹Rheumatology, Royal National Hospital, Bath, United Kingdom, ²²Department of Rheumatology, NHS Grampian, Aberdeen, United Kingdom, ²³Department of Rhuematology, Royal Blackburn Hospital, Blackburn, United Kingdom, ²⁴Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ²⁵Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Published efficacy data for rituximab in SLE are complex with positive single-centre case series and negative randomised controlled trials. This may be due to…
Abstract Number: 2840 • 2014 ACR/ARHP Annual Meeting
Targeting the RhoA-Rock Pathway to Reverse T Cell Dysfunction in SLE
Cristina T. Rozo¹, Laura Leuenberger², Kyriakos A. Kirou³, Margaret Robotham¹, Sanjay Gupta⁴, Reena Khianey², Alessandra B. Pernis⁴ and Jane E. Salmon², ¹535 East 70th Street, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Autoimmunity & Inflammation Research Program, Hospital for Special Surgery, New York, NY
Background/Purpose Aberrant expansion of TH-17 cells and deregulated production of IL-17 and IL-21 are involved in the pathogenesis of SLE. Production of IL-17 and IL-21…
Abstract Number: 2631 • 2014 ACR/ARHP Annual Meeting
Overall Cause and Cause-Specific Mortality in a Multinational Inception Cohort of SLE
Murray B. Urowitz¹, Dafna D. Gladman¹, Nicole Anderson², Dominique Ibanez³ and Systemic Lupus International Collaborating Clinics (SLICC)⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital Research Institute, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Hospital, Division of Rheumatology, University of Toronto, Toronto Western Hospital (Coordinating Center), Toronto, ON, Canada
Background/Purpose: A large multicenter multinational inception cohort was established initially to study risk factors for atherosclerosis (AS) in SLE. The aim of this study was…
Abstract Number: 1828 • 2014 ACR/ARHP Annual Meeting
Adverse Pregnancy Outcomes in Adolescents and Young Women with Systemic Lupus Erythematosus: A National Estimate
Nicole Ling¹, Isabel E. Allen², Erica F. Lawson¹ and Emily von Scheven³, ¹Pediatrics, University of California, San Francisco, San Francisco, CA, ²Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ³Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Pregnant women with SLE have increased risk of adverse outcomes including lupus flare, spontaneous abortion, preeclampsia/eclampsia, premature birth and maternal death, but pregnancy outcomes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].